Post-doctorat à Toulouse

Duration: 2 years minimum (starting date: 04/11/2019)

Location: Team: High Density Lipoprotein and PI3K signaling in atherosclerosis. Inserm UMR1048. Institute of Cardiovascular and Metabolic Diseases (I2MC), Toulouse.

Website: http://www.i2mc.inserm.fr/index.php/en/research-teams/team-5

Contact: Laurent.martinez@inserm.fr

Description of the institute of metabolic and cardiovascular diseases (I2MC)

The I2MC is located in Toulouse and is one of the larger institute in France dedicated to metabolic and cardiovascular diseases. The main feature of I2MC is the gathering of basic scientists together with clinicians working on metabolic risk factors (obesity, diabetes and dyslipidemia) and their cardiovascular complications (thrombosis, atherosclerosis, cardiac and renal failure). I2MC is composed of 13 research teams. The position is available in the research team of Laurent Martinez. The team is focused on the metabolic and vascular atheroprotective functions of High Density Lipoproteins (HDL), from molecular, cellular and preclinical research to clinical investigations in human cohorts.

Job description

A new postdoctoral position is available on a project related to non-alcoholic fatty liver disease (NAFLD)

NAFLD is a chronic disease that has become pandemic, as it affects between 20% and 30% of the general adult population of most Westernized countries. Although most cases of NAFLD follow a benign course, approximatively 20% evolve into an aggressive form termed non-alcoholic steatohepatitis (NASH), an aggressive form of NAFLD predisposing to an increased risk of cardiovascular and progressive liver diseases, including fibrosis, cirrhosis and hepatocellular carcinoma. The HDL particles remove cholesterol from arteries and tissues to transport it back to the liver for storage, recycling, and elimination through a pathway called “Reverse Lipid Transport (RLT)”. Thus, improving HDL-mediated lipid transport is expected to decrease vascular and hepatic lipid deposition. This opens up new therapeutic perspectives for the development of therapies against cardiovascular and metabolic diseases, including NAFLD.

The scientific goal of the post-doc mission will to better characterize novel HDL-related pathways and to analyze their contribution to lipid metabolism and NAFLD development. Effect of these pathways on the vasculature will be also investigated. Results will serve to the clinical validation of novel therapeutic compounds. He/she will use various experimental models (primary hepatocytes, adipocytes, original transgenic mice and murine models of NASH) and a large panel of methods and technical approaches (e.g. immunofluorescence, histology, HTRF, live-cell metabolic assay, lipidomics, RNA-Seq).

Profile

Post-doctoral applicants should have a PhD in cell biology, biochemistry, or a related field with an experience in the fields of lipoprotein metabolism and NAFLD (preferably both). An expertise in cellular and whole body lipid metabolism and immunometabolism is recommended. Experiments will involve animal models of NAFLD, cell biology, lipidomics, transcriptomic and bioinformatic analyses, with the support of local technical platforms. Motivation and ability to function autonomously is required. Prior experience international experience will constitute an advantage. Proven ability to identify research objectives, self-motivation, flexibility, and assistance to others ongoing research works are essential. The project is granted by industry and a regional plan on translational research in oncology and ageing (région Occitanie).

 

Applicants should send in a single PDF file: curriculum vitae, statements of research interests and technical skills, a brief description of career goals, and the names and contact information

of two references.